Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis

NCT ID: NCT01396343

Last Updated: 2018-10-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1276 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to better understand multiple sclerosis (MS) in children and adolescents, to learn if it differs from adult MS and to investigate if genes or environmental exposures or a combination of both put children and adolescents at risk for getting MS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall goal of this project is to determine whether well-established environmental and genetic risk factors for adult onset MS play an important role in susceptibility to pediatric-onset MS. Our study design is based on the hypothesis that genetic influences, specifically variation at HLA-DRB1 and other confirmed non-MHC MS loci, as well as environmental exposures including EBV infection and tobacco smoke, contribute to disease risk. In addition, we will also examine the relationship between serum levels of 25(OH) vitamin D3 and prior vitamin D status, and risk for pediatric onset MS. Finally, we will investigate whether specific G x E, and other multivariable relationships influencing risk exist for pediatric-onset MS. There are 16 collaborating sites other than UCSF that will enroll cases and controls for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediatric Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pediatric MS Case

Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection

No interventions assigned to this group

Pediatric Control

Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* They have MS or clinically isolated syndrome (CIS):

* MS: As defined by the 2010 McDonald criteria for diagnosis of MS (Polman 2010),
* CIS: A first demyelinating event indicating high risk for MS (i.e., one clinical event involving the spinal cord, the optic nerve, the brainstem or cerebellum, or occasionally the hemispheres) and at least 2 silent T2 bright areas on a brain or spinal cord MRI (at least one must be in the brain); AND
* They are three years of age or older; AND
* Disease onset occurred before 18 years of age.

Patients are not eligible for study participation if:

* Disease onset occurred more than 4 years prior to the opportunity to enroll; OR
* They have had an organ transplant; OR
* They are known to have neuromyelitis optica (NMO).

Children are not eligible to participate as pediatric controls if:

* They are two years of age or younger; OR
* They are 22 years of age or older; OR
* They are known to have MS or another demyelinating disease (for example, neuromyelitis optica or acute disseminated encephalomyelitis); OR
* They have a biological family member who has been enrolled as a control; OR
* They have an immediate, biological family member (parent/sibling) who has been diagnosed with MS; OR
* They have an autoimmune disorder (except asthma or eczema); OR
* They have had an organ transplant; OR
* They have a chronic neurological condition with major disability (this does not include, for example, migraine, controlled seizures, and mild learning disabilities such as ADD or ADHD).
Minimum Eligible Age

3 Years

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

New York University

OTHER

Sponsor Role collaborator

Massachusetts General Hospital

OTHER

Sponsor Role collaborator

State University of New York at Buffalo

OTHER

Sponsor Role collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role collaborator

Mayo Clinic

OTHER

Sponsor Role collaborator

Children's Hospital of Philadelphia

OTHER

Sponsor Role collaborator

Boston Children's Hospital

OTHER

Sponsor Role collaborator

Baylor College of Medicine

OTHER

Sponsor Role collaborator

Loma Linda University

OTHER

Sponsor Role collaborator

Children's Hospital Colorado

OTHER

Sponsor Role collaborator

University of Texas

OTHER

Sponsor Role collaborator

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

Sponsor Role collaborator

Washington University School of Medicine

OTHER

Sponsor Role collaborator

Children's National Research Institute

OTHER

Sponsor Role collaborator

Primary Children's Hospital

OTHER

Sponsor Role collaborator

The Cleveland Clinic

OTHER

Sponsor Role collaborator

University of California, San Francisco

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emmanuelle L Waubant, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Center for pediatric-onset demyelinating diseases at the Children's Hospital of Alabama, Birmingham

Birmingham, Alabama, United States

Site Status

Pediatric MS Clinic, Children's Hospital, Loma Linda University

San Bernardino, California, United States

Site Status

UCSF Pediatric MS Center

San Francisco, California, United States

Site Status

Children's Hospital Colorado, University of Colorado School of Medicine

Aurora, Colorado, United States

Site Status

Pediatric MS Clinic, Children's National Medical Center

Washington D.C., District of Columbia, United States

Site Status

Pediatric MS Clinic, Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Site Status

Partners Pediatric MS Center at the Massachusetts General Hospital for Children

Boston, Massachusetts, United States

Site Status

Pediatric MS Clinic, Children's Hospital Boston

Boston, Massachusetts, United States

Site Status

Regional Pediatric MS Center at Mayo Clinic

Rochester, Minnesota, United States

Site Status

Pediatric MS Clinic, Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Pediatric MS Center of the Jacobs Neurological Institute, University of Buffalo

Buffalo, New York, United States

Site Status

New York University Langone Medical Center

New York, New York, United States

Site Status

The Cleveland Clinic

Cleveland, Ohio, United States

Site Status

Pediatric MS Clinic, Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

Pediatric MS Center, University of Texas, Southwestern Medical Center

Dallas, Texas, United States

Site Status

The Blue Bird Circle Clinic for MS at Texas Children's Hospital

Houston, Texas, United States

Site Status

Pediatric Neurology Clinic, Primary Children's Hospital

Salt Lake City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

5R01NS071463

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.